Canada the First to Approve Phase 2b Trial of Abivax’s ABX464 for Ulcerative Colitis
News
Canada has become the first country to fully authorize a Phase 2b clinical trial that will explore Abivax‘s lead candidate ABX464 in patients with ulcerative colitis, the company announced. ABX464 ... Read more